Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHT post-marketing safety surveillance of Entresto for hypertension in Japan
jRCT2031230283Completed
- Sponsor
- Novartis
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sacubitril + valsartan in hypertension (HTN), sponsored by Novartis. Primary endpoint: Percentage of patients with hypotension, hyperkalemia, and renal impairment/failure. Started Sep 2023; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on jRCT2031230283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230283.